NasdaqCM - Nasdaq Real Time Price USD
Cadrenal Therapeutics, Inc. (CVKD)
16.45
-0.05
(-0.30%)
At close: May 2 at 4:00:00 PM EDT
16.00
-0.45
(-2.74%)
After hours: May 2 at 7:29:29 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
Operating Expense
10,960.62
10,960.62
7,632.84
Operating Income
-10,960.62
-10,960.62
-7,632.84
Net Non Operating Interest Income Expense
309.25
309.25
231.99
Other Income Expense
--
--
-956.23
Pretax Income
-10,651.37
-10,651.37
-8,357.09
Net Income Common Stockholders
-10,651.37
-10,651.37
-8,357.09
Diluted NI Available to Com Stockholders
-10,651.37
-10,651.37
-8,357.09
Basic EPS
-8.73
--
-9.29
Diluted EPS
-8.73
--
-9.29
Basic Average Shares
1,219.55
--
899.47
Diluted Average Shares
1,219.55
--
899.47
Total Operating Income as Reported
-10,960.62
-10,960.62
-7,632.84
Total Expenses
10,960.62
10,960.62
7,632.84
Net Income from Continuing & Discontinued Operation
-10,651.37
-10,651.37
-8,357.09
Normalized Income
-10,651.37
-10,651.37
-7,400.85
Interest Income
309.25
309.25
249.09
Interest Expense
--
--
17.10
Net Interest Income
309.25
309.25
231.99
EBIT
-10,651.37
-10,651.37
-8,339.99
EBITDA
-10,649.49
-10,649.49
-8,338.01
Reconciled Depreciation
1.88
1.88
1.98
Net Income from Continuing Operation Net Minority Interest
-10,651.37
-10,651.37
-8,357.09
Total Unusual Items Excluding Goodwill
--
--
-956.23
Total Unusual Items
--
--
-956.23
Normalized EBITDA
-10,649.49
-10,649.49
-7,381.77
12/31/2023 - 1/20/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ICU SeaStar Medical Holding Corporation
1.2850
-1.15%
ZVSA ZyVersa Therapeutics, Inc.
0.6100
-1.45%
SLRX Salarius Pharmaceuticals, Inc.
0.6900
-2.68%
VRPX Virpax Pharmaceuticals, Inc.
0.2750
+5.77%
KTTA Pasithea Therapeutics Corp.
1.4000
-7.89%
OBIO Orchestra BioMed Holdings, Inc.
2.7400
-0.36%
EVFM Evofem Biosciences, Inc.
0.0090
+4.65%
NTHI NeOnc Technologies Holdings, Inc. Common Stock
5.36
0.00%
IKT Inhibikase Therapeutics, Inc.
2.2500
+0.45%
CHRO Channel Therapeutics Corporation
1.2600
+0.80%